Shots:
The first patient has been dosed in the P-III (EFZO-FIT) study to evaluate the efficacy and safety of the efzofitimod (3.0/5.0mg/kg) vs PBO in 264 patients with pulmonary sarcoidosis at multiple centers in North America, EU & Japan
The 1EPs of the study will evaluate the steroid-sparing effect while the 2EPs include measures of lung function and sarcoidosis symptoms
The (EFZO-FIT) study builds on the results from P-Ib/IIa study which showed a dose-dependent improvement across steroid reduction, lung function & symptom control EPs. Efzofitimod is an immunomodulator that selectively modifies NRP2 to suppress innate and adaptive immune responses in uncontrolled inflammatory disease conditions
Ref: Globenewswire | Image: aTyr Pharma
